ArticleIranian journal of pharmaceutical research : IJPR2022

A Phase I Randomized, Double-blind, Placebo-controlled Study on Efficacy and Safety Profile of a Sublingually Administered Cannabidiol /Delta 9-tetrahydrocannabidiol (10: 1) Regimen in Diabetes Type 2 Patients.

Shima Afshar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.